PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|August 30, 2019
Oval Relocates to Cambridge Research Park in the UK
Author(s)Pharmaceutical Technology Editors
Oval Medical Technologies (Oval) has revealed that it is relocating to a specifically designed facility in Cambridge Research Park in the United Kingdom as a result of growth.
Advertisement
Patient-centric autoinjector specialist, Oval Medical Technologies (Oval), has revealed that it is relocating to a specifically designed facility in Cambridge Research Park in the United Kingdom as a result of growth.
In an Aug. 22, 2019 press release, Oval confirmed that the new facility will incorporate dedicated good manufacturing practice labs, increased capacity for the expanded team, and room for further growth, which the company predicts will result from increasing demand by pharma companies for injection platforms to deliver subcutaneous and intramuscular formulations.
“Our autoinjector platforms are creating huge opportunities for pharmaceutical companies to develop new products and to improve established formulations,” said Barbara Lead, CEO of Oval Medical Technologies, in the press release. “This move provides the needed space to continue to grow and develop cutting edge technology platforms serving pharmaceutical companies and patients.”
“Our principal aim is to partner our patient-centric autoinjectors with an integrated start to finish solution-one that’s easy for patients and easy for partners. Our expanded new facility makes that objective more achievable,” added Oval’s chief technology officer, Matthew Young, in the press release.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5